ReviewFrontiers in pharmacology2025
The role of trimethylamine N-oxide in disease pathogenesis and the therapeutic potential of traditional Chinese medicine.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Microbiota-Mediator-Host Signaling Networks in Metabolic Syndrome: From Mechanistic Insights to Therapeutic Targeting.Microorganisms · 2026Review
- The Application of Metabolomics in Frailty: Trends, Challenges, and Future Directions.Metabolites · 2026Review
- The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets.Probiotics and antimicrobial proteins · 2026Review
- The essential role of hydrogen gas recycling by gut microbes in reducing deuterium load in host mitochondria: is trimethylamine oxide a deuterium sensor?Metabolomics : Official journal of the Metabolomic Society · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trimethylamine N-oxide (TMAO), a metabolite derived from gut microbiota, has been implicated in the pathogenesis of various chronic diseases, including cardiovascular, digestive, neurological, and renal disorders. This review explores the complex mechanisms by which TMAO contributes to disease progression, including its role in inflammation, oxidative stress, and metabolic disorders. The study focused on the potential of traditional Chinese medicine (TCM) to regulate TMAO levels and mitigate its adverse effects. TCM interventions, through modulation of gut microbiota and inhibition of key enzymes like flavin-containing monooxygenase 3 (FMO3), offer promising therapeutic avenues. Despite the positive outcomes observed in preliminary studies, further research is needed to fully elucidate the mechanisms by which TCM interacts with TMAO and to establish its efficacy in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.